The Blind Bridge

Types of Blindness

In short

Blindness isn’t one condition — it’s many, from macular degeneration and glaucoma to diabetic retinopathy, each affecting vision differently. The reassuring news: most types are manageable or treatable, especially caught early, and total blindness is rare — most blind people have some usable vision. This guide covers the 10 major types in plain language: what each is, the early signs, how it usually progresses, what doctors can do as of October 2026, and where to find support.

Blindness is not one thing. It is many different conditions, each affecting vision in its own way — some take the center of your sight, some take the edges, some arrive at birth and some arrive at eighty. This guide walks through the main ones in plain language: what each condition is, the early signs people notice, how it usually progresses, what doctors can do about it as of October 2026, and where to find people who understand.

Legal blindness, low vision, and total blindness: what the words mean

These three terms get mixed up constantly, and the differences matter — especially because "legally blind" is a legal and benefits category, not a description of seeing nothing at all.

Legal blindness is the U.S. government's definition, used by the Social Security Administration to decide eligibility for disability benefits and other programs. You are considered legally blind if your central vision is 20/200 or worse in your better eye, even with your best glasses or contact lenses — or if your visual field is 20 degrees or less in your better eye. Having 20/200 vision means you would need to stand 20 feet from something that a person with typical vision could see from 200 feet away. Most people who are legally blind still have some usable vision.

Low vision means significant vision loss that glasses, contact lenses, medicine, or surgery cannot fully correct. It is usually described as vision that cannot be corrected better than about 20/70 — you can see, but not well enough for everyday tasks without help, and standard glasses are not enough to fix it. Low vision is the territory where magnifiers, screen readers, and other tools start to matter.

Total blindness means no usable vision at all — no ability to tell light from dark. It is the rarest of the three. The vast majority of blind people, including most who are legally blind, have some remaining sight, such as light perception, color, or a narrow patch of vision.

The details of the legal definition come from the Social Security Administration's criteria, summarized in the National Library of Medicine's medical reference on blindness.

Age-related macular degeneration (AMD)

What it is: AMD damages the macula, the small central part of the retina responsible for sharp, straight-ahead vision. It is the leading cause of vision loss and blindness for Americans aged 65 and older, according to the National Eye Institute. The rest of the retina keeps working, so people with AMD keep their side (peripheral) vision even as the center goes.

Dry AMD

What it is: Dry AMD is the more common form. Waste deposits called drusen build up under the macula, and over time patches of retinal tissue waste away. The advanced stage is called geographic atrophy — patches of the macula literally die off, creating expanding blind spots in central vision.

Early signs people notice: Blurry or fuzzy spots in the center of vision; straight lines (doorframes, text lines) looking wavy or bent; needing brighter light to read; colors looking less vivid; trouble recognizing faces.

How it typically progresses: Slowly, over years. Dry AMD can stay mild for a long time, advance to geographic atrophy, or convert into wet AMD — which is why doctors monitor it with regular eye exams and imaging.

Treatments as of October 2026: For intermediate dry AMD, eye doctors commonly recommend a specific vitamin formula developed from the National Eye Institute's AREDS2 study, which has been shown to slow progression. For advanced dry AMD (geographic atrophy), the FDA approved the first-ever treatments in 2023: Syfovre (pegcetacoplan) and Izervay (avacincaptad pegol), both given as eye injections. They work by calming an overactive part of the immune system (the complement pathway) that drives retinal cell death. They slow the growth of the atrophic lesions — they do not bring back vision that is already lost.

Wet AMD

What it is: In wet (neovascular) AMD, abnormal blood vessels grow under the macula and leak fluid or blood, damaging it quickly. It is less common than dry AMD but causes most of the severe vision loss from the disease.

Early signs people notice: A sudden or rapid worsening of central vision — straight lines looking wavy, a dark or empty spot in the center of vision, or vision that changes quickly over days or weeks. Rapid change in one eye is a reason to call an eye doctor promptly.

How it typically progresses: Faster than dry AMD. Without treatment, leaking vessels can scar the macula and central vision can drop sharply.

Treatments as of October 2026: The main treatment is anti-VEGF injections into the eye — drugs that block a protein (vascular endothelial growth factor) driving the abnormal vessel growth. Common ones include Eylea (aflibercept), Lucentis (ranibizumab), Avastin (bevacizumab, used off-label for the eye), Beovu (brolucizumab), and Vabysmo (faricimab). Most people need injections monthly at first, then often less frequently. Anti-VEGF treatment improves vision in about one in three people and stabilizes it for the large majority, according to the American Academy of Ophthalmology.

Where to get support:

Glaucoma

What it is: Glaucoma is a group of eye diseases that damage the optic nerve — the cable carrying visual information from the eye to the brain. It is usually tied to pressure inside the eye being too high, though it can happen at normal pressures too. It is a leading cause of irreversible blindness worldwide. Vision lost to glaucoma cannot be restored, which is why early detection matters so much.

Open-angle glaucoma

What it is: The most common type. The eye's drainage system slowly clogs over time, like a sink draining too slowly, and pressure builds gradually.

Early signs people notice: There are essentially none — no pain, no warning. Open-angle glaucoma is famously called the "silent thief of sight." By the time it is noticed, it usually shows up as patchy blind spots in side (peripheral) vision.

How it typically progresses: Slowly, over years. Side vision narrows bit by bit; if untreated, it can narrow to tunnel vision and eventually take central vision too. It often affects both eyes, though one may be worse.

Treatments as of October 2026: Treatment aims to lower eye pressure and stop further damage — it cannot undo damage already done. Prescription eye drops that lower pressure are usually the first step. Laser procedures and surgery are options when drops are not enough. Because there are no early symptoms, regular eye exams with pressure checks are the only reliable way to catch it early.

Angle-closure glaucoma

What it is: The drainage angle of the eye gets suddenly blocked — usually by the iris — and pressure spikes fast.

How it typically progresses: Unlike open-angle glaucoma, this is an attack, not a slow fade. Some people have warning episodes of milder symptoms before a full attack.

Where to get support:

Diabetic retinopathy

What it is: A complication of diabetes in which high blood sugar damages the tiny blood vessels of the retina. The vessels can leak fluid or bleed, and in advanced stages fragile new abnormal vessels grow on the retina's surface (proliferative diabetic retinopathy), which can bleed into the eye or pull the retina out of place. Swelling of the macula (diabetic macular edema) is another common vision-stealing part of the disease.

Early signs people notice: Often none at all in the early stages. Later: blurred or fluctuating vision, floaters or dark spots, dark or empty areas in vision, and trouble reading or seeing detail up close. Because early disease is silent, people with diabetes need regular dilated eye exams even when their vision feels fine.

How it typically progresses: It moves through stages — from mild vessel changes, to leaking and swelling, to the growth of fragile new vessels that can bleed or cause retinal detachment. Good blood sugar, blood pressure, and cholesterol control slows it down, but does not guarantee it stops.

Treatments as of October 2026: Doctors choose based on the stage. Anti-VEGF eye injections are the usual first-line treatment for swelling of the macula and can also help proliferative disease. Laser treatment (photocoagulation) seals leaking vessels or treats the oxygen-starved outer retina to stop new vessel growth. Vitrectomy surgery — removing the gel inside the eye — is used in advanced cases with bleeding that will not clear or scar tissue pulling on the retina. An NEI-supported clinical trial found that injections and surgery lead to similar outcomes for bleeding inside the eye from advanced disease, giving doctors and patients real choices.

Where to get support:

Retinitis pigmentosa

What it is: Not one disease but a family of inherited retinal diseases. Changes (mutations) in any of dozens of genes cause the retina's light-sensing cells to break down over time — the rod cells that handle night and side vision usually go first, followed later by the cone cells that handle central and color vision.

Early signs people notice: Trouble seeing at night or in dim restaurants and theaters (night blindness) is usually first. Then side vision gradually narrows — bumping into doorframes, missing things off to the side — eventually leaving tunnel vision. It often starts in childhood or young adulthood.

How it typically progresses: Slowly, over decades, and very differently from person to person — even within the same family. Some people keep useful central vision for most of their lives; others progress to very limited vision.

Treatments as of October 2026: There is no cure for most forms yet. The exception is Luxturna (voretigene neparvovec), a one-time gene therapy given as an injection under the retina, FDA-approved in 2017 — but only for people with confirmed mutations in both copies of the RPE65 gene, a small subset of cases. This is why genetic testing matters: it identifies the exact gene involved, gives a clearer picture of what to expect, and can qualify you for clinical trials of emerging therapies, which researchers are actively studying for other RP genes. Day to day, low-vision rehabilitation and assistive technology make the biggest practical difference.

Where to get support:

Cataracts

What it is: A clouding of the eye's natural lens — like looking through a frosted window. Cataracts are overwhelmingly a part of aging; most people will develop some lens clouding if they live long enough. They can also result from injury, certain medications such as steroids, or other eye conditions.

Early signs people notice: Blurry or hazy vision that new glasses do not fix; glare and halos around headlights and lamps at night; colors looking faded or yellowed; needing brighter light to read; sometimes double vision in one eye.

How it typically progresses: Gradually — months to years. Early on, stronger lighting and new glasses may be enough. Eventually the clouding interferes with reading, driving, recognizing faces, and daily life. Unlike most conditions on this page, cataract vision loss is reversible.

Treatments as of October 2026: Cataract surgery is the fix, and it is one of the most common and successful surgeries performed anywhere — millions of Americans have it each year. The surgeon removes the cloudy natural lens and replaces it with a permanent artificial one (an intraocular lens, or IOL) that needs no care. It is usually an outpatient procedure, and most people see clearly again within days. No eye drops, diet, or exercise has been shown to dissolve a cataract; surgery is the treatment.

Where to get support: Talk to your eye doctor about timing — the usual advice is to consider surgery when the cataract starts interfering with the life you want to live. The National Eye Institute publishes plain-language cataract information for patients and families.

Stargardt disease

What it is: The most common inherited macular dystrophy — sometimes called juvenile macular degeneration. It is usually caused by mutations in the ABCA4 gene, which leave the retina unable to clear away the toxic waste produced from using vitamin A. That waste builds up in the macula and destroys central vision. It most often shows up in childhood, the teens, or young adulthood, though later onset happens too.

Early signs people notice: Blurry central vision that glasses do not correct; a gray, hazy, or blind spot in the center of vision; trouble seeing fine detail or reading; colors looking washed out. Side vision is usually preserved, even late in the disease.

How it typically progresses: Gradual loss of central vision over years. Earlier onset generally means faster progression. Peripheral vision typically remains, so most people with Stargardt do not lose all sight — but reading, recognizing faces, and detail work become very difficult.

Treatments as of October 2026: There are no approved treatments yet. Researchers are actively running clinical trials on several approaches — including oral medications that slow the toxic waste buildup, gene therapies, and cell-based treatments — and early results presented in 2026 have been encouraging. For now, management focuses on low-vision aids, rehabilitation, UV protection for the eyes, and avoiding high-dose vitamin A supplements (which can add to the waste buildup) unless a doctor advises otherwise.

Where to get support:

Optic neuritis

What it is: Inflammation of the optic nerve — the cable connecting the eye to the brain. It is often an early sign of multiple sclerosis (MS): the National Eye Institute reports that over half of people with a first episode of optic neuritis will eventually develop MS. It can also occur with other autoimmune conditions or infections, and sometimes no cause is found.

Early signs people notice: Vision in one eye becomes blurry, dim, or washed out — colors may look faded — often developing over hours or days. There is frequently pain around the eye, especially when moving it. Most episodes affect one eye at a time.

How it typically progresses: Vision usually bottoms out within a week or two, then improves over the following weeks — many people recover much of their vision. But episodes can recur, and each attack carries some risk of lasting damage. Because of the MS connection, doctors usually order an MRI of the brain after a first episode to assess future risk.

Treatments as of October 2026: High-dose corticosteroids given intravenously speed up visual recovery, based on the landmark Optic Neuritis Treatment Trial — though they do not change the final level of recovery compared with no treatment. Oral steroids alone are not recommended. If MS is diagnosed, disease-modifying MS therapies are used to reduce future attacks. Anyone with optic neuritis should also be evaluated for related conditions such as neuromyelitis optica.

Where to get support:

Retinopathy of prematurity (ROP)

What it is: An eye disease of premature babies. In a full-term baby, the retina's blood vessels finish growing before birth; in babies born very early or at very low birth weight, the vessels stop growing and then abnormal, fragile vessels can grow instead — which can scar and pull the retina out of place.

Early signs people notice: Parents cannot see ROP — there are no visible symptoms in the early stages. That is why premature babies at risk are examined by an ophthalmologist in the hospital, usually starting a few weeks after birth, with follow-up exams on a strict schedule. Later, ROP can raise the risk of nearsightedness, crossed eyes (strabismus), lazy eye, and glaucoma, which is why these children need ongoing eye care as they grow.

How it typically progresses: Many mild cases resolve on their own as the baby grows and are simply watched. More severe disease can progress to retinal detachment and permanent vision loss if not treated in time — which is why the screening schedule matters so much.

Treatments as of October 2026: The standard treatment is laser photocoagulation, which treats the outer retina to stop abnormal vessel growth. Anti-VEGF injections into the eye are increasingly used, especially for disease at the back of the eye — they preserve more of the peripheral retina, but babies need extended follow-up because the disease can reactivate later. Older freezing treatment (cryotherapy) has largely been replaced by laser. If the retina detaches, surgery (scleral buckling or vitrectomy) may be needed.

Where to get support:

Leber congenital amaurosis (LCA)

What it is: A group of inherited retinal diseases that cause severe vision loss from birth or the first months of life. It is one of the earliest-appearing causes of blindness in children. Babies with LCA respond poorly to visual cues — they may not track faces or objects — and the eyes themselves can look typical even though vision is profoundly affected.

Early signs people notice: Parents usually notice in the first months: the baby does not follow objects or faces with their eyes, does not reach for toys visually, or seems not to notice light changes. An eye doctor finds the retina not responding normally to light.

How it typically progresses: It varies by gene — LCA can be caused by mutations in many different genes. Vision is usually severely limited from the start; some children retain a small amount of usable vision, and the course differs from child to child.

Treatments as of October 2026: Luxturna (voretigene neparvovec), the gene therapy given as a one-time injection under the retina, is FDA-approved for LCA caused by mutations in both copies of the RPE65 gene — but that accounts for only a minority of LCA cases. For the other genes, there is no approved treatment yet, though researchers are actively studying gene therapies for several of them. Genetic testing is the critical first step: it identifies the gene, clarifies the prognosis, and determines eligibility for Luxturna or clinical trials. Early intervention services, orientation and mobility training, and braille or assistive technology support matter from the start.

Where to get support:

Cortical / cerebral visual impairment (CVI)

What it is: CVI is different from every other condition on this page: the eyes themselves are typically healthy, but the brain's visual pathways and processing centers are damaged — most often by a lack of oxygen around birth or by premature birth. The eyes capture the picture fine; the brain cannot make full sense of it. It is the most common cause of severe visual impairment and blindness in children in developed countries, and it is frequently underdiagnosed because standard eye exams can look normal.

Early signs people notice: CVI looks different in every child, and a child's vision can vary with fatigue, illness, or environment. Common patterns include: difficulty recognizing faces or finding objects in clutter; trouble with crowded or busy visual scenes; looking away when reaching for something; staring at lights; problems with depth perception or seeing movement; and vision that seems better in familiar, simplified settings.

How it typically progresses: Unlike degenerative eye diseases, CVI is a brain-based condition, and many children's functional vision improves over time — especially with the right support. The brain's plasticity in childhood works in their favor.

Treatments as of October 2026: There is no surgery or medicine that fixes CVI. Support focuses on understanding how the individual child sees and adapting their world: reducing visual clutter, using high-contrast and simplified materials, controlling lighting, and working with specialists experienced in CVI assessment and educational strategies. An accurate diagnosis matters because CVI needs a completely different approach than eye-based vision loss.

Where to get support:

  • Ask your pediatric ophthalmologist for a referral to a specialist experienced in CVI — standard low-vision approaches designed for eye conditions often miss what a child with CVI needs.
  • The Pediatric Cortical Visual Impairment Society connects families and professionals focused specifically on CVI.
  • For the science-minded, an NIH-published review of how CVI affects the brain's visual wiring explains why CVI behaves so differently from eye-based blindness.

Just diagnosed?

A diagnosis — yours or someone you love — can feel like the floor dropped out. Here is the most important thing to know first: a diagnosis is the beginning of figuring things out, not the end of them. Blind and low-vision people live full, working, traveling, joking, ordinary-and-extraordinary lives, and there is a well-worn path from where you are now to where you are going. You do not have to walk it alone, and you do not have to figure everything out this week.

Practical first steps: keep every follow-up appointment with your eye doctor and ask them to explain the diagnosis in plain language — it is their job, and you are allowed to ask twice. Get a referral to low-vision rehabilitation services, which teach the skills and tools for daily life with the vision you have. And reach out to the organizations listed above for your condition — talking to people who have been where you are helps.

When you are ready for the bigger picture — the skills, the technology, the community, and how to rebuild daily life — our Start Here guide is the front door. It is organized around where you are right now, whether you just lost vision yourself or someone you love did.

A note on medical information

This guide is information, not medical advice. Eye conditions are individual — two people with the same diagnosis can have very different experiences and different right answers. Treatments change as research advances; what is listed here reflects what was current as of October 2026. For decisions about your eyes or your child's eyes, talk to your eye doctor — an ophthalmologist or optometrist who knows your specific situation.